

Discovery of CLIPS™ binders to anti-TNF α mAb's using Phage Display Libraries

Michael Goldflam¹, Peter Timmerman¹, Bradley T. Messmer², Fabio M. Spiga³

1. Pepscan Presto, Zuidersluisweg 2, 8243 RC Lelystad, The Netherlands
 2. Abreos Biosciences, 3550 General Atomics Ct, Bldg G02, RM 137, San Diego, USA
 3. Creoptix AG, Zugstrasse 76, 8820 Wädenswil, Switzerland
- m.goldflam@pepscan.com; p.timmerman@pepscan.com; info@pepscan.com


"When linear is not enough..."

PEPSCAN


Intro

Mimotope peptides selected from combinatorial peptide libraries can be used as capture reagents for immunoassay detection of therapeutic monoclonal antibodies (mAbs).¹ Previous attempts by Abreos, independent of Pepscan, to identify peptide-binders from 7aa and 12aa linear peptides and C7C and 7C7C7 SS-looped peptide libraries did not yield any hits that showed reproducible binding in ELISA. Here we report the use of a monocyclic phage library encoding for a fully randomized 10-mer peptide sequence flanked by two cysteines that are linked via a CLIPS™ scaffold (A_CT₂XXXXXXXXXXC_T2G) to identify peptide binders (Veritopes™) that bind to Infliximab (brandname *Remicade*™), a therapeutic mAb indicated to treat autoimmune diseases like Rheumatoid Arthritis (RA) and Crohn's Disease.


CLIPS™ scaffold Chemistry²




Methodology: Phage Display Screening



Target Binding Sites




Best Lead Peptide




Sequence*	EC ₅₀ (ng/mL)
Lead (T2-13)	35
Linear/SS-loop	>1000
Scrambled-1/2/3	>1000
Lead (T2-42/57)	>1000

*sequence was anonymized for confidentiality reasons

ELISA binding-data



GCI binding data



Conclusion: Successful identification of nM CLIPS-binder to Infliximab where other technologies failed sofar.

References: 1. Ruff LE et al., *Sci. Rep.* **2018**, 8, 14473; 2. Timmerman P et al. *Chem-Biochem* **2005**, 6, 821-4; 3. Liang SY et al. *J. Biol. Chem.* **2013**, 288, 13799-807.